SINOVAC Biotech Ltd. ("SINOVAC") is a China-based leading biopharmaceutical company that focuses on the research, development, production, and commercialization of vaccines that protect against human infectious diseases.
More2026/03/30
BEIJING, March 27, 2026 — Sinovac Holding Group (“SINOVAC”) and Bio Farma, Indonesia's state-owned pharmaceutical company, signed a strategic memorandum of understanding in Beijing on March 27, 20
BEIJING, January 27, 2026 – Co-administration of SINOVAC's Sabin-strain inactivated poliovirus vaccine (sIPV) with either measles-mumps-rubella (MMR) or inactivated hepatitis A (HepA) vaccines is
2026/01/27
BEIJING, January 22, 2026 – Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (
2026/01/22
BEIJING, January 20, 2026 – A large-scale real-world study published in the peer-reviewed journal Vaccines showed that SINOVAC's live attenuated varicella vaccine (VarV) has a stable and favorable
2026/01/20
SINOVAC has undertaken nearly 60 national and regional science and technology
R&D projects; received two State Scientific and Technology Progress Awards
and three national-level institutional technology awards; and published more than
140 SCI papers, many of which were published in top academic journals including
New England Journal of Medicine, The Lancet, Science and Nature, etc.
SINOVAC approved products include: COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac®, Enterovirus Type 71 Vaccine (Vero cell), Inactivated - Inlive®, Hepatitis A Vaccine (Human Diploid Cell) Inactivated - Healive®, Influenza Vaccine (Split Virion), Inactivated - Anflu®, 23-valent Pneumococcal Polysaccharide Vaccine, Varicella Vaccine(Live), Mumps Vaccine(Live), etc.